Levobren

Levosulpiride, the active ingredient in Levobren, is a benzamide antipsychotic presented as an injectable solution for intramuscular and intravenous use. It treats schizophrenia, depressive disorders, and functional dyspepsia in adult patients and acts as a selective dopamine D2 receptor antagonist with prokinetic activity.

GNH USA supplies Levobren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to GMP standards and provides regulatory‑compliant shipments to healthcare facilities across the globe.

Levosulpiride is used in psychiatric and gastrointestinal disorders that involve dopaminergic dysregulation.

- Schizophrenia: reduces positive and negative symptoms by blocking dopamine D2 receptors. - Depressive disorders: augments antidepressant response in patients with psychotic features. - Functional dyspepsia: improves gastric motility and relieves dyspeptic symptoms through prokinetic activity.

Levosulpiride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: mild sedation or fatigue. - Extrapyramidal symptoms: tremor, rigidity, or akathisia. - Nausea: gastrointestinal upset. - Elevated prolactin: menstrual disturbances or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Severe extrapyramidal reactions: tardive dyskinesia or acute dystonia. - Cardiac arrhythmias: QT prolongation or other rhythm disturbances.

When prescribing Levosulpiride, clinicians should consider several safety and handling precautions. - Renal impairment: adjust monitoring as the drug is excreted unchanged. - Hepatic disease: use with caution due to limited metabolism data. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: may be excreted in milk; consider alternatives. - Elderly patients: increased sensitivity to extrapyramidal effects; start low. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosulpiride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antipsychotics with strong D2 antagonism: may increase risk of extrapyramidal symptoms. - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., fluconazole): may raise plasma levels. - Dopamine agonists (e.g., levodopa): antagonistic effect reducing therapeutic benefit. - Anticholinergics: may mask extrapyramidal signs.